24 results
424B5
MREO
Mereo Biopharma Group Plc
14 Jun 24
Prospectus supplement for primary offering
4:15pm
instituted securities class action litigation against the issuer of such securities. If any of the holders of ADSs were to bring such a lawsuit against us … , we could incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an “affirmative defense” in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.
A Trading Plan must either (1
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
litigation against the issuer of such securities. If any of the holders of ADSs were to bring such a lawsuit against us, we could incur substantial costs … defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination
424B5
hmvtqdef
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
2ob2iuv prtf
9 Feb 21
Prospectus supplement for primary offering
5:24pm
424B5
o5uavhxy5 k68
23 Oct 20
Prospectus supplement for primary offering
4:40pm
F-3
x4eh2
6 Oct 20
Shelf registration (foreign)
4:25pm
6-K
EX-10.1
0aol43 oy43
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
F-1/A
xjgo3enrxqlc8a7uxw
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
6aswyo
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
EX-10.1
t6p6hct4lev
3 Sep 19
Current report (foreign)
4:05pm
20-F
8fmjqkrw93lzsb3i8
29 Apr 19
Annual report (foreign)
4:59pm